Dr O'Malley Discusses ARIEL4 Trial Results: Rucaparib Promising for BRCA+ Relapsed Ovarian Cancer

David O'Malley, MD, OSUCCC- James, highlights promising results following ARIEL4, an exploratory subgroup analysis that investigated the effect of platinum sensitivity on the efficacy of rucaparib vs chemotherapy for BRCA-mutated, advanced, relapsed ovarian carcinoma.

10 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Stay in the know.
OncNet Newsletter